Tekmira Selloff Could Be Exaggerated Print E-mail
By Brian Wilson - Lead Contributor   
Monday, 07 July 2014 08:30
On July 3rd of last week, Tekmira (TKMR) fell over 15% after the FDA put a clinical hold on the company’s Phase I trial for TKM-Ebola – an early-stage RNAi therapeutic for the
Ebola virus.
Read more...
 
Could Amarin Return From The Dead? Print E-mail
By Brian Wilson - Lead Contributor   
Wednesday, 02 July 2014 04:11
After Amarin (AMRN) failed to gain FDA approval for a sNDA that would’ve allowed its triglyceride-lowering omega-3 drug Vascepa to be marketed to patients with “high” TG levels (200-500 mg/dL), the market pretty much left the

Error. Page cannot be displayed. Please contact your service provider for more details. (14)

stock for dead after it dropped to 52-week lows of $1.28 per share.
Read more...
 
This Bottom Bouncer Looks Primed To Pick Up More Traction Print E-mail
By M.E.Garza   
This low float biotech stock which has several catalysts on tap appears ready to head higher after a very recent trend reversal.
Read more...
 
Mixed Feelings Drive MannKind After FDA Approval Print E-mail
By Brian Wilson - Lead Contributor   
Monday, 30 June 2014 08:09
The retail-driven action in MannKind (MNKD) wasn’t clearly bullish or bearish after the company received an early approval for Afrezza from the FDA last Friday.
Read more...
 
Should Investors Consider Aerie Pharma? Print E-mail
By Brian Wilson   
Thursday, 26 June 2014 09:35
Aerie Pharmaceuticals (AERI) is an ophthalmology product developer that focuses on products that treat glaucoma – an progressive eye condition that leads to damage of the optic nerve and vision loss.
Read more...
 
Agile Therapeutics Jumps 35% on a Patent Extension Print E-mail
By Brian Wilson - Lead Contributor   
Tuesday, 24 June 2014 08:59
Reminding us that low volume and low float stocks can move dramatically with a single press release, women’s health company Agile Therapeutics (AGRX) moved 35% higher yesterday after it was announced that the company received an extension on a patent for a transdermal contraceptive known as Twirla.
Read more...
 
New Verastem Data Expected In 2014 Print E-mail
By Brian Wilson - Lead Contributor   
Monday, 23 June 2014 08:01
Verastem (VSTM) is a modestly-priced oncology company that focuses on targeting cancer stem cells.
Read more...
 
Three Ways to Spot Weak Data from Bad Biotechs Print E-mail
By Staff and Wire Reports   
Friday, 20 June 2014 13:21
  I have trouble understanding the mentality of investors who throw huge amounts of money at biotech & pharma companies that they don't actually understand.
Read more...
 
Flexion Sees A Delayed Pop On New Data Print E-mail
By Brian Wilson - Lead Contributor   
Thursday, 19 June 2014 08:10
Earlier this week, Flexion Therapeutics (FLXN) announced topline results from the Phase IIA portion of its Phase II trial for FX006 – a non-opioid steroid treatment that is designed to provide long-term pain reduction in patients with osteoarthritis of the knee (OAK.)
Read more...
 
Endocyte Hit Hard After Merck Drops Partnership Print E-mail
By Brian Wilson - Lead Contributor   
Wednesday, 18 June 2014 07:56
Endocyte (ECYT) is a cancer drug developer that was largely known for the non-small cell lung, breast, and late-stage cancer therapy Vynfinit (vintafolide, or EC145) that was being developed in partnership with Merck.
Read more...
 
<< Start < Prev 11 12 13 14 15 16 17 18 19 20 Next > End >>

Page 11 of 55
BMR:1